Michael F. Crutchlow

Author

University of Pennsylvania ORCID

Also Known As

M.F. Crutchlow, MICHAEL CRUTCHLOW, Michael Crutchlow, Michael F Crutchlow, Michael F. Crutchlow

Publications

839

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Merck & Co., Inc., Rahway, NJ, USA (United States)Precision Research Institute Children's Hospital of Philadelphia

About

Michael F. Crutchlow is an author at University of Pennsylvania specializing in medicine, diabetes, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	261
2	Cell Biology	2	2	184
3	Diabetes	2	2	212
4	Health Sciences	1	1	39
5	Biochemistry	1	1	39

Michael F. Crutchlow

Publications

540

Citations

H-Index

Page 1

	Year	Citations
The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice Jennifer Oliver‐Krasinski, Margaret Kasner, Juxiang Yang, Journal of Clinical Investigation Systems BiologyDevelopmental BiologyTranscriptional NetworkTranscription Factor NetworkPancreatic Cancer	2009	173
Calcineurin Signaling Regulates Human Islet β-Cell Survival Scott A. Soleimanpour, Michael F. Crutchlow, Alana Ferrari, Journal of Biological Chemistry	2010	144
Identification of transcriptional targets during pancreatic growth after partial pancreatectomy and exendin-4 treatment Diva D. De León, Cyrus Farzad, Michael F. Crutchlow, Physiological Genomics	2006	46
Clinical Evaluation of <scp>MK</scp>‐2640: An Insulin Analog With Glucose‐Responsive Properties Alexander W. Krug, Sandra A. G. Visser, Kuenhi Tsai, Clinical Pharmacology & Therapeutics Metabolic SyndromeTranslational MedicineType 1Diabetes ManagementBiochemistry	2018	39
Exendin-4 Normalizes Islet Vascularity in Intrauterine Growth Restricted Rats: Potential Role of VEGF J. Nina Ham, Michael F. Crutchlow, Biva M. Desai, Pediatric Research Regenerative MedicineAngiogenesisDevelopmental BiologyGrowth HormoneHuman Growth	2009	38
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between <scp>MK</scp> ‐1293 insulin glargine and originator insulin glargine ( <scp>L</scp> antus) in subjects with type 1 diabetes and healthy subjects Michael F. Crutchlow, John Palcza, Kate Mostoller, Diabetes Obesity and Metabolism	2017	20
Direct Comparison of Radioimmunoassay and LC–MS/MS for PK Assessment of Insulin Glargine in Clinical Development Yang Xu, Marita Prohn, Xiaoyan Cai, Bioanalysis	2014	16
Validation of Steady-State Insulin Sensitivity Indices in Chronic Kidney Disease Michael F. Crutchlow, Bruce Robinson, Binu Pappachen, Diabetes Care	2007	15
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018 Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Annals of Hepatology	2023	14
Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study Juan P. Frías, Zachary Zimmer, Raymond L. H. Lam, Diabetes Obesity and Metabolism	2019	12

Page 1